Germany· DE-A57-a69d87878af3c5fd
Nilotinib Ratiopharm
A nilotinib product containing nilotinib hydrochloride dihydrate, registered in Germany by Ratiopharm Gmbh. The same ATC class is registered in 14 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Nilotinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EA03 (nilotinib), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Nilotinib · ATC L01EA03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nilotinib costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nilotinib · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$56.31
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Nilotinib Hydrochloride Dihydrate
- Manufacturer
- Ratiopharm Gmbh
- Country
- Germany (DE)
- ATC code
- L01EA03
- ATC class
- Nilotinib
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
756 interactions on record for nilotinib.
Graded by severity as the source publishes them — 303 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nilotinib · interactions on record
756 records
- 303 severe
- 433 moderate
- 20 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EA03
Nilotinib, as other registers publish it.
- CanadaAPO-NILOTINIBAPOTEX INC
- CanadaAPO-NILOTINIBAPOTEX INC
- United StatesCAVHANZACycle Pharmaceuticals Ltd
- United StatesCAVHANZACycle Pharmaceuticals Ltd
- United StatesCAVHANZACycle Pharmaceuticals Ltd
- United StatesCAVHANZACycle Pharmaceuticals Ltd
- United StatesDANZITENAzurity Pharmaceuticals, Inc.
- United StatesDANZITENAzurity Pharmaceuticals, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac61d74a-e768-4c80-9a55-f1f248d5d1f8 GET /v1/drugs/ac61d74a-e768-4c80-9a55-f1f248d5d1f8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Nilotinib Hydrochloride Dihydrate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about nilotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.